title: [KRAS mutation testing in therapeutic algorithm for treatment of metastatic colorectal carcinoma].
abstract: Targeted therapy has become an integral part of treatment procedures of malignant tumors. Colorectal carcinomas are frequently targeted with monoclonal anti-EGFR antibodies (cetuximab and panitumumab). Activating somatic mutations in codons 12 and 13 of the exon 2 of KRAS gene are considered negative predictive factors of response to anti-EGFR therapy in patients with metastatic colorectal cancer. In the Czech Republic, evaluation of mutational status of KRAS gene is performed in several referral laboratories. In 2009, these laboratories performed 2580 tests of the KRAS mutational status--out of these, 60.2% cases reported non-mutated, wild-type KRAS. In one of the referral laboratories, we demonstrate the logistics of KRAS testing procedure. Stratification of patients with metastatic colorectal tumors based on their KRAS mutational status has evolved to a standard procedure. Laboratories performing these methods shall therefore adhere to the recommendations of the professional and accredited societies.
authors.affiliation: Oddeleni laboratorní medicíny, Masarykův onkologický ustav, Brno dubska@mou.cz
authors.forename: Lenka
authors.initials: L
authors.lastname: Dubská
authors.forename: Martina
authors.initials: M
authors.lastname: Vyskocilová
authors.forename: Rudolf
authors.initials: R
authors.lastname: Nenutil
authors.forename: Dalibor
authors.initials: D
authors.lastname: Valík
authors.forename: Dana
authors.initials: D
authors.lastname: Knoflícková
authors.forename: Pavel
authors.initials: P
authors.lastname: Fabian
authors.forename: Ilona
authors.initials: I
authors.lastname: Kocáková
authors.forename: Regina
authors.initials: R
authors.lastname: Demlová
authors.forename: Martin
authors.initials: M
authors.lastname: Beránek
authors.forename: Monika
authors.initials: M
authors.lastname: Drastíková
authors.forename: Hana
authors.initials: H
authors.lastname: Vosmiková
authors.forename: Arpád
authors.initials: A
authors.lastname: Bóday
authors.forename: Katerina
authors.initials: K
authors.lastname: Horká
authors.forename: Jarmila
authors.initials: J
authors.lastname: Símová
authors.forename: Jirí
authors.initials: J
authors.lastname: Drábek
authors.forename: Jirí
authors.initials: J
authors.lastname: Ehrmann
authors.forename: Marián
authors.initials: M
authors.lastname: Hajdúch
authors.forename: Milada
authors.initials: M
authors.lastname: Matejcková
authors.forename: Radek
authors.initials: R
authors.lastname: Síma
authors.forename: Daniel
authors.initials: D
authors.lastname: Tvrdík
authors.forename: Ctibor
authors.initials: C
authors.lastname: Povýsil
authors.forename: Ales
authors.initials: A
authors.lastname: Ryska
mesh_terms: D000911:Antibodies, Monoclonal / Q000627:therapeutic use; D061067:Antibodies, Monoclonal, Humanized; D000970:Antineoplastic Agents / Q000627:therapeutic use; D000068818:Cetuximab; D015179:Colorectal Neoplasms / Q000188:drug therapy* / Q000235:genetics* / Q000473:pathology / Q000556:secondary; D011905:Genes, ras / Q000235:genetics*; D006801:Humans; D009154:Mutation; D000077544:Panitumumab
chemical_list: D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D000970:Antineoplastic Agents; D000077544:Panitumumab; D000068818:Cetuximab